Medical Meetings

Learn about the latest myeloma research. Get a front row seat at the most critical medical meetings. Watch Dr. Brian Durie, IMF Chairman, address issues that are important to the entire myeloma community. IMF TV brings it all to you.

Dec
04
Predictors of T Cell Expansion and Clinical Responses Following CART-BCMA for Relapsed/Refractory Multiple Myeloma
In this study, we found that CART-BCMA expansion and responses in heavily-pretreated MM patients were not associated with tumor burden or other clinical characteristics, but did correlate with(...)
Dec
04
NKG2D-CAR Transduced Primary Natural Killer Cells Efficiently Target Multiple Myeloma Cells
Immunotherapy represents a new weapon in the fight against multiple myeloma. Current clinical outcomes using CAR-T cell therapy against multiple myeloma show promise in the eradication of the disease(...)
Dec
04
Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory Multiple Myeloma
P-BCMA-101 is a novel chimeric antigen receptor (CAR)-T cell therapeutic targeting BCMA, which is highly expressed on MM cells. It is designed to increase efficacy while minimizing toxicity through(...)
Dec
04
Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Venetoclax (Ven), an oral agent that targets the antiapoptotic protein, BCL-2, has demonstrated efficacy, as monotherapy and combined with proteasome inhibitor (PI) bortezomib, in relapsed/refractory(...)
Dec
04
串联自体移植 和CD19的联合输液 和Bcma特异性CAR T细胞 对于高风险MM
Multiple myeloma (MM) is an incurable plasma cell malignancies despite the advent of numerously new drugs. Survival was poor particularly for high risk patients such as R-ISS stage III. The(...)
Dec
04
One-Year Update of Alcyone: Phase 3 Randomized Study of D-VMP Versus VMP in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma
With 1 year of additional follow-up, the combination of DARA and VMP in transplant ineligible NDMM pts continues to demonstrate a significant PFS benefit, including in pts ≥75 years of age, and(...)